- HFpEF = HF symptoms + EF ≥50% + proof of high filling pressure (BNP, E/e′, LA size, or invasive).
- Use H₂FPEF (or HFA-PEFF) when unsure. Obesity lowers BNP.
- Rule out mimics: ATTR amyloid, HCM, valve disease, constriction, high-output states.
- 2026 ACC pathway — backbone = SGLT2i + finerenone (finerenone is the MRA of choice; spironolactone if not feasible).
- BMI ≥30 → add a GLP-1 RA or tirzepatide (STEP-HFpEF, SUMMIT).
- Diuretics for congestion. β-blockers only for a reason (AF rate, angina, post-MI).
Pathophysiology in 60 seconds
⌄
- Stiff LV + stiff vessels + systemic inflammation from visceral fat → high LV filling pressure at rest or with exercise.
- The 2026 view: HFpEF is a multisystem cardio-kidney-metabolic syndrome, not "just diastolic dysfunction."
- Exercise → pressure spikes → lung congestion → dyspnea. AF, HTN, CKD, obesity and anemia all add load.
HFrEF is a weak pump. HFpEF is a strong pump stuck in a too-small, stiff balloon — every extra drop of volume raises pressure a lot.
Diagnosis
⌄
| H₂FPEF item | Points |
|---|---|
| Heavy: BMI >30 | 2 |
| Hypertensive: ≥2 BP drugs | 1 |
| Fibrillation (AF) | 3 |
| Pulmonary HTN: PASP >35 mmHg | 1 |
| Elder: age >60 | 1 |
| Filling: E/e′ >9 | 1 |
0–1 low probability · 2–5 intermediate (consider BNP, exercise echo / invasive test) · 6–9 high probability.
- ATTR cardiac amyloid: age >65, bilateral carpal tunnel, spinal stenosis, biceps rupture, low-voltage ECG with thick walls, troponin always a little high → PYP/DPD scan + serum free light chains & SPEP/UPEP/immunofixation (rule out AL first). Treatment: tafamidis / acoramidis.
- HCM · moderate–severe AS/MR · constrictive pericarditis · high-output (anemia, AV fistula, thyroid, liver) · pulmonary arterial hypertension.
Management (2026 ACC pathway)
⌄
| Therapy | Who | Dose / note |
|---|---|---|
| SGLT2i (empagliflozin, dapagliflozin) | All confirmed HFpEF | 10 mg daily |
| Finerenone | Most patients (K ≤5.0, eGFR ≥25) | Start 10–20 mg daily by eGFR; titrate; check K in 4 weeks |
| Spironolactone | If finerenone not possible (cost, access) | 12.5–25 mg daily |
| GLP-1 RA / tirzepatide | BMI ≥30 | Semaglutide 2.4 mg weekly or tirzepatide — weight, symptoms, HF events |
| ARNI / ARB | Consider, esp. EF in lower range (≤55–60), women | Sacubitril/valsartan 24/26 → 97/103 BID |
| Loop diuretic | Congestion | Lowest dose that keeps euvolemia |
| β-blocker | Only with AF, angina, post-MI | Not routine (blunts heart-rate reserve) |
- Treat BP (<130/80), AF (consider rhythm control), sleep apnea, CKD, diabetes.
- Exercise training and weight loss improve symptoms.
Pitfalls
⌄
- Labeling every dyspneic obese patient "HFpEF" without objective data.
- Missing amyloid (and starting high-dose β-blockers/digoxin, poorly tolerated).
- Over-diuresis → AKI, hypotension (small, stiff LV is preload-dependent).
- Rate too slow — HFpEF patients need heart-rate reserve.
Board corner
⌄
| Stem | Answer |
|---|---|
| 78-year-old man, bilateral carpal tunnel, LVH, low voltage | ATTR amyloid → PYP scan + light chains |
| HFpEF, best proven first drug | SGLT2 inhibitor |
| HFpEF + BMI 38 | Add GLP-1 RA / tirzepatide |
| HFpEF, MRA of choice (2026) | Finerenone |
| EF 55%, dyspnea, BMI 32, BNP normal | Obesity lowers BNP → H₂FPEF / exercise testing |
References
⌄
- Kittleson MM, et al. 2026 ACC Expert Consensus Decision Pathway on HFpEF. J Am Coll Cardiol. 2026.
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA HF guideline.
- EMPEROR-Preserved · DELIVER · FINEARTS-HF · STEP-HFpEF · SUMMIT · PARAGON-HF.
- Reddy YNV, et al. H₂FPEF score. Circulation. 2018;138:861.